Clinical Trial Update: A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program [Phase 3]

View source ↗

Summary

Phase 3 study evaluating tirzepatide in adults with obesity after a lifestyle weight loss program has completed, with results posted in May 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Tirzepatide (tirzepatide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity, Overweight | Phase 3 | Status: COMPLETED | Results posted: 2024-05-16